ARK Invest Loads Up on Meta (META) Stock with $38M Buy While Exiting CrowdStrike (CRWD)

Key Takeaways

• Cathie Wood’s ARK Invest acquired 51,477 Meta Platforms shares valued at approximately $38 million across three ETFs
• Meta stock jumped approximately 11.5% following excitement surrounding Muse, its innovative AI agent application
• ARK divested 28,403 CrowdStrike shares worth approximately $7 million during the same trading session
• Despite CrowdStrike’s nearly 5% gain, ARK reduced its holdings in the cybersecurity firm
• Meta Connect conference is scheduled for September 23-24, featuring CEO Mark Zuckerberg’s presentations on AI innovations and wearable technology

On Monday, September 21, 2026, Cathie Wood’s ARK Invest executed two significantly different portfolio decisions. The investment firm accumulated a substantial position in Meta Platforms while simultaneously reducing its CrowdStrike holdings, despite both technology stocks experiencing gains during the session.

Meta Platforms experienced an impressive surge of approximately 11.5% during Monday’s trading. This dramatic price movement was largely attributed to increasing enthusiasm surrounding Muse, Meta’s newly released personal AI agent application. The app achieved the number one position on Apple’s U.S. free-app download rankings, signaling strong initial adoption among consumers.

Meta Platforms, Inc., META

Muse represents a significant evolution beyond conventional chatbot technology. The application possesses capabilities to compose and send emails, arrange travel accommodations, complete digital forms, and execute online transactions autonomously on users’ behalf.

ARK’s Meta acquisition involved purchasing 51,477 shares distributed among its ARKK, ARKW, and ARKF exchange-traded funds. The combined transaction value reached approximately $38 million.

The upcoming Meta Connect conference, slated for September 23-24, will feature CEO Mark Zuckerberg presenting updates on artificial intelligence innovations and wearable technology developments. This event may provide investors with deeper insights into Muse’s roadmap and Meta’s comprehensive AI strategy.

Analyst sentiment toward Meta remains overwhelmingly bullish. The stock carries a Strong Buy consensus rating from 44 Wall Street analysts, comprising 38 Buy recommendations and 6 Hold ratings. The consensus price target of $763.67 suggests approximately 3% potential appreciation from present trading levels.

ARK Reduces CrowdStrike Stake Amid Stock Gains

CrowdStrike shares advanced nearly 5% on Monday. The cybersecurity sector received support from investor expectations that AI agent proliferation could dramatically increase the number of digital endpoints requiring security protection.

Notwithstanding this positive price action, ARK divested 28,403 CrowdStrike shares via its ARKW and ARKF funds. The transaction totaled approximately $7 million in value.

CrowdStrike recently hosted its Fal.Con conference, where company leadership unveiled innovative solutions designed for the emerging AI agent landscape. These include an Agentic Identity Provider platform and specialized products focused on securing artificial intelligence workloads.

The cybersecurity company has delivered exceptional performance throughout 2026. Year-to-date, shares have surged approximately 113%. In the most recent quarterly report, annual recurring revenue expanded 25% to reach $5.84 billion, while net new ARR skyrocketed 51% to achieve a record $333 million.

CrowdStrike similarly enjoys a Strong Buy consensus among Wall Street analysts, backed by 31 Buy ratings and 7 Hold ratings. The average analyst price target of $247.10 trades marginally below Monday’s closing level of $249.35.

Additional Portfolio Adjustments in Healthcare Sector

Beyond these prominent transactions, ARK expanded positions across multiple biotechnology companies. The firm acquired 102,565 Beam Therapeutics shares, 100,241 Ionis Pharmaceuticals shares, and 74,878 Veracyte shares through its ARKG ETF.

ARK additionally purchased 29,587 Airbnb shares via its ARKW ETF, representing a transaction value of approximately $4.9 million.

Among portfolio reductions, ARK liquidated positions in Everpure and 10x Genomics, while also selling a modest quantity of ARK 21Shares Bitcoin ETF shares.

ARK further acquired 61,858 Scribe Therapeutics shares, demonstrating sustained commitment to gene-editing innovations.